AMSTERDAM (360Dx) – As infections that require quick and accurate treatments become more prevalent, and antimicrobial resistance remains a global problem, a growing number of companies are developing new antimicrobial susceptibility testing (AST) platforms to address urgent clinical needs, executives said this week at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Amsterdam.
At the conference several firms spoke about the seemingly intractable issue of antimicrobial resistance and new technologies being developed to tackle the problem.